mRNA-1195.1

Phase 1RNA therapy

Moderna

mRNA-1195.1 is one of 7 biologic programs targeting Epstein-Barr virus infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epstein-Barr Virus InfectionActive, not recruiting

Epstein-Barr Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Epstein-Barr Virus Infection

#DrugCompanyPhaseTrials

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Taxol

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adrucil

Gemzar

GGynecologic Oncology Group

Mrna-1195

1 7

mRNA-1195.1

Moderna

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Epstein-Barr Virus Infection

NCT05831111

Clinical

Trials by Indication[1]

Epstein-Barr virus infection1 trial

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Participants 18 Through 55 Years of Age

Active, not recruiting· Moderna logo

Moderna·Phase 1·NCT05831111·482 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-1195.1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1195.1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1195.1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: Moderna

mRNA-1195.1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Epstein-Barr virus infection1 trial

References

Drug Info

Quick Facts

Related News